1932

Abstract

Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20 years with the introduction of new oral and inhaled medications as well as novel surgical and bronchoscopic procedures. This article summarizes some of the recent advances in our understanding of disease pathogenesis and treatment paradigms.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-080919-112707
2021-01-27
2024-06-22
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-080919-112707.html?itemId=/content/journals/10.1146/annurev-med-080919-112707&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Fishman AP. 2005. One hundred years of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171:9941–48
    [Google Scholar]
  2. 2. 
    Soriano JB, Abajobir AA, Abate KH et al. 2017. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 5:9691–706
    [Google Scholar]
  3. 3. 
    Kochanek KD, Murphy SL, Xu J, Arias E 2017. Mortality in the United States, 2016 NCHS Data Brief 293, National Center for Health Statistics Hyattsville, MD:
    [Google Scholar]
  4. 4. 
    Fletcher C, Peto R. 1977. The natural history of chronic airflow obstruction. Br. Med. J. 1:60771645–48
    [Google Scholar]
  5. 5. 
    Lange P, Celli B, Agustí A et al. 2015. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 373:2111–22
    [Google Scholar]
  6. 6. 
    Den Dekker HT, Jaddoe VWV, Reiss IK et al. 2018. Fetal and infant growth patterns and risk of lower lung function and asthma. Am. J. Respir. Crit. Care Med. 197:2183–92
    [Google Scholar]
  7. 7. 
    Belgrave DCM, Granell R, Turner SW et al. 2018. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. Lancet Respir. Med. 6:7526–34
    [Google Scholar]
  8. 8. 
    Casas M, Den Dekker HT, Kruithof CJ et al. 2018. The effect of early growth patterns and lung function on the development of childhood asthma: a population based study. Thorax 73:121137–45
    [Google Scholar]
  9. 9. 
    Bui DS, Lodge CJ, Burgess JA et al. 2018. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir. Med. 6:7535–44
    [Google Scholar]
  10. 10. 
    Heijink IH, Noordhoek JA, Timens W et al. 2014. Abnormalities in airway epithelial junction formation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 189:111439–42
    [Google Scholar]
  11. 11. 
    Staudt MR, Buro-Auriemma LJ, Walters MS et al. 2014. Airway basal stem/progenitor cells have diminished capacity to regenerate airway epithelium in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 190:8955–58
    [Google Scholar]
  12. 12. 
    Burgel PR, Bourdin A, Chanez P et al. 2011. Update on the roles of distal airways in COPD. Eur. Respir. Rev. 20:1197–22
    [Google Scholar]
  13. 13. 
    Yang J, Zuo WL, Fukui T et al. 2017. Smoking-dependent distal-to-proximal repatterning of the adult human small airway epithelium. Am. J. Respir. Crit. Care Med. 196:3340–52
    [Google Scholar]
  14. 14. 
    Boucher RC. 2019. Muco-obstructive lung diseases. N. Engl. J. Med. 380:201941–53
    [Google Scholar]
  15. 15. 
    Kesimer M, Ford AA, Ceppe A et al. 2017. Airway mucin concentration as a marker of chronic bronchitis. N. Engl. J. Med. 377:10911–22
    [Google Scholar]
  16. 16. 
    Martinez FJ, Han MK, Allinson JP et al. 2018. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 197:121540–51
    [Google Scholar]
  17. 17. 
    Hogg JC, Paré PD, Hackett TL 2017. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol. Rev. 97:2529–52
    [Google Scholar]
  18. 18. 
    Hogg JC, Macklem PT, Thurlbeck WM 1968. Site and nature of airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. 278:251355–60
    [Google Scholar]
  19. 19. 
    McDonough JE, Yuan R, Suzuki M et al. 2011. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365:171567–75
    [Google Scholar]
  20. 20. 
    Martinez CH, Mannino DM, Jaimes FA et al. 2015. Undiagnosed obstructive lung disease in the United States. Associated factors and long-term mortality. Ann. Am. Thorac. Soc. 12:121788–95
    [Google Scholar]
  21. 21. 
    Han MLK, Min GK, Mardon R et al. 2007. Spirometry utilization for COPD: How do we measure up. Chest 132:2403–9
    [Google Scholar]
  22. 22. 
    Siu AL, Bibbins-Domingo K, Grossman DC et al. 2016. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA 315:131372–77
    [Google Scholar]
  23. 23. 
    Labaki WW, Han MLK. 2018. Improving detection of early chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 15:Suppl. 4S243–48
    [Google Scholar]
  24. 24. 
    Martinez FJ, Mannino D, Leidy NK et al. 2017. A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 195:6748–56
    [Google Scholar]
  25. 25. 
    Singh D, Agusti A, Anzueto A et al. 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur. Respir. J. 53:51900164
    [Google Scholar]
  26. 26. 
    Pellegrino R, Viegi G, Brusasco V et al. 2005. Interpretative strategies for lung function tests. Eur. Respir. J. 26:5948–68
    [Google Scholar]
  27. 27. 
    Çolak Y, Afzal S, Nordestgaard BG et al. 2018. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur. Respir. J. 51:31702681
    [Google Scholar]
  28. 28. 
    Bhatt SP, Balte PP, Schwartz JE et al. 2019. Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality. JAMA 321:242438–47
    [Google Scholar]
  29. 29. 
    Pauwels RA, Buist AS, Calverley PMA et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163:51256–76
    [Google Scholar]
  30. 30. 
    Rabe KF, Hurd S, Anzueto A et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176:6532–55
    [Google Scholar]
  31. 31. 
    Mannino DM. 2006. GOLD stage 0 COPD: Is it real? Does it matter. Chest 130:2309–10
    [Google Scholar]
  32. 32. 
    Tan WC, Bourbeau J, Hernandez P et al. 2014. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 69:8709–17
    [Google Scholar]
  33. 33. 
    Martinez CH, Kim V, Chen Y et al. 2014. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir. Med. 108:3491–99
    [Google Scholar]
  34. 34. 
    Wijnant SRA, de Roos E, Kavousi M et al. 2020. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam study. Eur. Respir. J. 55:11901217
    [Google Scholar]
  35. 35. 
    Woodruff PG, Barr RG, Bleecker E et al. 2016. Clinical significance of symptoms in smokers with preserved pulmonary function. N. Engl. J. Med. 374:191811–21
    [Google Scholar]
  36. 36. 
    Mets OM, Buckens CFM, Zanen P et al. 2011. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA 306:161775–81
    [Google Scholar]
  37. 37. 
    Regan EA, Lynch DA, Curran-Everett D et al. 2015. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern. Med. 175:91539–49
    [Google Scholar]
  38. 38. 
    Galbán CJ, Han MK, Boes JL et al. 2012. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat. Med. 18:111711–15
    [Google Scholar]
  39. 39. 
    Bhatt SP, Soler X, Wang X et al. 2016. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 194:2178–84
    [Google Scholar]
  40. 40. 
    Vasilescu DM, Martinez FJ, Marchetti N et al. 2019. Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 200:5575–81
    [Google Scholar]
  41. 41. 
    Sin DD, Vestbo J. 2009. Biomarkers in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6:6543–45
    [Google Scholar]
  42. 42. 
    Agustí A, Edwards LD, Rennard SI et al. 2012. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLOS ONE 7:5e37483
    [Google Scholar]
  43. 43. 
    Dahl M, Vestbo J, Lange P et al. 2007. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175:3250–55
    [Google Scholar]
  44. 44. 
    Butler CC, Gillespie D, White P et al. 2019. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N. Engl. J. Med. 381:2111–20
    [Google Scholar]
  45. 45. 
    Mannino D, Tal-Singer R, Lomas D et al. 2014. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chronic Obstr. Pulm. Dis. 2:123–34
    [Google Scholar]
  46. 46. 
    Vedel-Krogh S, Nielsen SF, Lange P et al. 2016. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 193:9965–74
    [Google Scholar]
  47. 47. 
    Pascoe S, Barnes N, Brusselle G et al. 2019. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir. Med. 7:9745–56
    [Google Scholar]
  48. 48. 
    Yonchuk JG, Silverman EK, Bowler RP et al. 2015. Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. Am. J. Respir. Crit. Care Med. 192:7785–92
    [Google Scholar]
  49. 49. 
    Çolak Y, Afzal S, Nordestgaard BG et al. 2020. Prevalence, characteristics, and prognosis of early chronic obstructive pulmonary disease the Copenhagen general population study. Am. J. Respir. Crit. Care Med. 201:6671–80
    [Google Scholar]
  50. 50. 
    Lowe KE, Regan EA, Anzueto A et al. 2019. COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr. Pulm. Dis. 6:5384–99
    [Google Scholar]
  51. 51. 
    Tashkin DP, Celli B, Senn S et al. 2008. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359:151543–54
    [Google Scholar]
  52. 52. 
    Zhou Y, Zhong N, Li X et al. 2017. Tiotropium in early-stage chronic obstructive pulmonary disease. N. Engl. J. Med. 377:10923–35
    [Google Scholar]
  53. 53. 
    Martinez FJ, Fabbri LM, Ferguson GT et al. 2017. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest 152:61169–78
    [Google Scholar]
  54. 54. 
    Halpin DM, Miravitlles M, Metzdorf N et al. 2017. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int. J. COPD. 12:2891–908
    [Google Scholar]
  55. 55. 
    Wedzicha JA, Banerji D, Chapman KR et al. 2016. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374:232222–34
    [Google Scholar]
  56. 56. 
    Lipson DA, Barnhart F, Brealey N et al. 2018. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 378:181671–80
    [Google Scholar]
  57. 57. 
    Lipson DA, Crim C, Criner GJ et al. 2020. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. Am. J. Respir. Crit. Care Med. 201:121508–16
    [Google Scholar]
  58. 58. 
    Chapman KR, Hurst JR, Frent SM et al. 2018. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 198:3329–39
    [Google Scholar]
  59. 59. 
    Watz H, Tetzlaff K, Wouters EFM et al. 2016. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 4:5390–98
    [Google Scholar]
  60. 60. 
    Deleted in proof
  61. 61. 
    Singh D, Bafadhel M, Brightling CE et al. 2020. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 202:5660–71
    [Google Scholar]
  62. 62. 
    Pavord ID, Chanez P, Criner GJ et al. 2017. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N. Engl. J. Med. 377:171613–29
    [Google Scholar]
  63. 63. 
    Criner GJ, Celli BR, Brightling CE et al. 2019. Benralizumab for the prevention of COPD exacerbations. N. Engl. J. Med. 381:111023–34
    [Google Scholar]
  64. 64. 
    Albert RK, Connett J, Bailey WC et al. 2011. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365:8689–98
    [Google Scholar]
  65. 65. 
    Han MLK, Tayob N, Murray S et al. 2014. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am. J. Respir. Crit. Care Med. 189:121503–8
    [Google Scholar]
  66. 66. 
    Calverley PM, Rabe KF, Goehring UM et al. 2009. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:9691685–94
    [Google Scholar]
  67. 67. 
    Swallow EB, Reyes D, Hopkinson NS et al. 2007. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62:2115–20
    [Google Scholar]
  68. 68. 
    Marquis K, Debigaré R, Lacasse Y et al. 2002. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166:6809–13
    [Google Scholar]
  69. 69. 
    Greening NJ, Harvey-Dunstan TC, Chaplin EJ et al. 2015. Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease. Am. J. Respir. Crit. Care Med. 192:7810–16
    [Google Scholar]
  70. 70. 
    Polkey MI, Praestgaard J, Berwick A et al. 2019. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease: a randomized trial. Am. J. Respir. Crit. Care Med. 199:3313–20
    [Google Scholar]
  71. 71. 
    Rochester CL, Vogiatzis I, Holland AE et al. 2015. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 192:111373–86
    [Google Scholar]
  72. 72. 
    Nishi SPE, Zhang W, Kuo YF et al. 2016. Pulmonary rehabilitation utilization in older adults with chronic obstructive pulmonary disease, 2003 to 2012. J. Cardiopulm. Rehabil. Prev. 36:5375–82
    [Google Scholar]
  73. 73. 
    Lindenauer PK, Stefan MS, Pekow PS et al. 2020. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 323:181813–23
    [Google Scholar]
  74. 74. 
    Rochester CL, Holland AE. 2020. Pulmonary rehabilitation and improved survival for patients with COPD. JAMA 323:181783–85
    [Google Scholar]
  75. 75. 
    Fishman A, Martinez F, Naunheim K et al. 2003. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 348:212059–73
    [Google Scholar]
  76. 76. 
    van Agteren JEM, Carson KV, Tiong LU et al. 2016. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst. Rev. 2016:10CD001001
    [Google Scholar]
  77. 77. 
    Decker MR, Leverson GE, Jaoude WA et al. 2014. Lung volume reduction surgery since the National Emphysema Treatment Trial: Study of Society of Thoracic Surgeons Database. J. Thorac. Cardiovasc. Surg. 148:62651–2658.e1
    [Google Scholar]
  78. 78. 
    Criner GJ, Cordova F, Sternberg AL et al. 2011. The National Emphysema Treatment Trial (NETT). Part II: Lessons learned about lung volume reduction surgery. Am. J. Respir. Crit. Care Med. 184:8881–93
    [Google Scholar]
  79. 79. 
    Criner GJ, Sue R, Wright S et al. 2018. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am. J. Respir. Crit. Care Med. 198:91151–64
    [Google Scholar]
  80. 80. 
    Criner GJ, Delage A, Voelker K et al. 2019. Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial. Am. J. Respir. Crit. Care Med. 200:111354–62
    [Google Scholar]
  81. 81. 
    Slebos DJ, Shah PL, Herth FJF et al. 2019. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am. J. Respir. Crit. Care Med. 200:121477–86
    [Google Scholar]
  82. 82. 
    Valipour A, Ing A, Williamson JP et al. 2019. First-in-human results of bronchial rheoplasty: an endobronchial treatment for chronic bronchitis (CB). Am. J. Respir. Crit. Care Med. 199:A7037 Abstr. )
    [Google Scholar]
  83. 83. 
    Valipour A, Ing A, Williamson J et al. 2018. Late breaking abstract—first-in-human results of bronchial rheoplasty: an endobronchial treatment for chronic bronchitis (CB). Eur. Respir. J. 52:OA2162 (Abstr.)
    [Google Scholar]
  84. 84. 
    Siddiqui FM, Diamond JM. 2018. Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr. Opin. Pulm. Med. 24:2199–204
    [Google Scholar]
  85. 85. 
    Weill D, Benden C, Corris PA et al. 2015. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 34:11–15
    [Google Scholar]
  86. 86. 
    Kvale PA, Conway WA, Coates EO 1980. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial. Ann. Intern. Med. 93:3391–98
    [Google Scholar]
  87. 87. 
    Albert RK, Au DH, Blackford AL et al. 2016. A randomized trial of long-term oxygen for COPD with moderate desaturation. N. Engl. J. Med. 375:171617–27
    [Google Scholar]
  88. 88. 
    Coleman JM, Wolfe LF, Kalhan R 2019. Noninvasive ventilation in chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 16:91091–98
    [Google Scholar]
  89. 89. 
    Murphy PB, Rehal S, Arbane G et al. 2017. Effect of home noninvasive ventilation with oxygen therapy versus oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 317:212177–86
    [Google Scholar]
  90. 90. 
    Köhnlein T, Windisch W, Köhler D et al. 2014. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir. Med. 2:9698–705
    [Google Scholar]
  91. 91. 
    Casanova C, Celli BR, Tost L et al. 2000. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 118:61582–90
    [Google Scholar]
  92. 92. 
    McEvoy RD, Pierce RJ, Hillman D et al. 2009. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 64:7561–66
    [Google Scholar]
/content/journals/10.1146/annurev-med-080919-112707
Loading
/content/journals/10.1146/annurev-med-080919-112707
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error